The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*
暂无分享,去创建一个
R. Schein | J. Dhainaut | D. Maki | P. Morris | P. Laterre | G. Garber | G. Kinasewitz | S. LaRosa | D. Heiselman | R. Light | J. Sollet | B. Utterback | H. Levy | Becky M Bates
[1] Thomas R. Riley,et al. A Randomized Double-blind Placebo-controlled Trial , 2004 .
[2] Rainald Fischer,et al. Daily hemodialysis and the outcome of acute renal failure. , 2002, The New England journal of medicine.
[3] E. Ivers,et al. Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .
[4] M Schetz,et al. Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.
[5] D. Moher,et al. The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.
[6] J Ean,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.
[7] R. Collins,et al. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.
[8] J. Dhainaut,et al. Perspectives in Anti-Inflammatory Therapies in Sepsis , 2001 .
[9] J. Pugin,et al. Evolving Concepts in Sepsis and Septic Shock , 2001, Perspectives on Critical Care Infectious Diseases.
[10] P. Sleight. Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them! , 2000, Current controlled trials in cardiovascular medicine.
[11] Rinaldo Bellomo,et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial , 2000, The Lancet.
[12] G Sherman,et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.
[13] M. Schaller,et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. , 1998, Critical care medicine.
[14] J. Bartlett,et al. GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA Community-Acquired Pneumonia in Adults: Guidelines for Management , 1998 .
[15] J. Bartlett,et al. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] R. Finch,et al. Design of clinical trials in sepsis: problems and pitfalls. , 1998, The Journal of antimicrobial chemotherapy.
[17] S. Opal,et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.
[18] C. Sprung,et al. Influence of alterations in forgoing life-sustaining treatment practices on a clinical sepsis trial , 1997 .
[19] C. Sprung,et al. Influence of alterations in foregoing life-sustaining treatment practices on a clinical sepsis trial. The HA-1A Sepsis Study Group. , 1997, Critical care medicine.
[20] M. Glauser,et al. International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. , 1996, Critical care medicine.
[21] J. Carlet,et al. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. , 1996, Critical care medicine.
[22] I. Olkin,et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.
[23] R A Weinstein,et al. Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. , 1996, JAMA.
[24] Kenneth F. Schulz,et al. The CONSORT Statement , 1996 .
[25] G. Koch,et al. Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .
[26] S. Nasraway,et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. , 1995, JAMA.
[27] J. Dhainaut,et al. Platelet-activating factor antagonists as therapeutic strategy in sepsis. , 1994, Progress in clinical and biological research.
[28] C. Sprung,et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .
[29] E. Draper,et al. APACHE II: A severity of disease classification system , 1985, Critical care medicine.
[30] J. Enders,et al. Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.